Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;14(4):356-63.
doi: 10.2174/1570159x14666151208114634.

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist

Jinglin Zhang, Louis Chew-Seng Tan  1
Affiliations
Review

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist

Jinglin Zhang et al. Curr Neuropharmacol. 2016.

Abstract

The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in "LD phobia" with clinicians selecting dopamine agonist (DA) over LD as initial therapy. More recently, a shift in the treatment approach towards initial LD use appears to be occurring. It is therefore necessary to review current evidence for the use of LD and DA. This review discusses the medical management of Parkinson's disease with regards to the use of LD versus DA. Pendulum swings in treatment strategies between LD-first and DA-first therapies should be avoided. A balanced perspective is needed as there is a place for both drugs in the management of PD.

PubMed Disclaimer

References

    1. Ferreira J.J., Katzenschlager R., Bloem B.R., Bonuccelli U., Burn D., Deuschl G., Dietrichs E., Fabbrini G., Friedman A., Kanovsky P., Kostic V., Nieuwboer A., Odin P., Poewe W., Rascol O., Sampaio C., Schüpbach M., Tolosa E., Trenkwalder C., Schapira A., Berardelli A., Oertel W.H. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur. J. Neurol. 2013;20(1):5–15. doi: 10.1111/j.1468-1331.2012.03866.x. - DOI - PubMed
    1. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology. 1991;41(2 ( Pt 1)):202–205. doi: 10.1212/WNL.41.2_Part_1.202. - DOI - PubMed
    1. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., Stocchi F. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord. 2004;19(9):997–1005. doi: 10.1002/mds.20243. - DOI - PubMed
    1. Olanow C.W. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology. 2009;72(7) Suppl.:S59–S64. doi: 10.1212/WNL.0b013e318199068b. - DOI - PubMed
    1. Kurlan R. “Levodopa phobia”: a new iatrogenic cause of disability in Parkinson disease. Neurology. 2005;64(5):923–924. doi: 10.1212/01.WNL.0000152880.77812.5B. - DOI - PubMed

Publication types

MeSH terms